SCHEMBL385458

SCHEMBL385458

CCOC(=O)c1[nH]c2ccc(OC(F)(F)F)cc2c1I

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.57
KDM4E B2RXH2 7/20 0.57
HPGD P15428 5/20 0.57
MAPT P10636 4/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
HSD17B10 Q99714 4/20 0.51
LMNA P02545 3/20 0.51
HTT P42858 1/20 0.51
GAA P10253 4/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTGS2 P35354 2/20 0.48
PTGS1 P23219 1/20 0.48
TUBB4A P04350 3/20 0.47
TUBB P07437 3/20 0.47
TUBA3C P0DPH7 3/20 0.47
TUBA1B P68363 3/20 0.47
TUBA4A P68366 3/20 0.47
TUBB4B P68371 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17600647 0.85 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL6923876 0.85 KDM4E (0.69) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL17600661 0.84 ALOX15 (0.57) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL7086632 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL862355 0.83 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL26213303 0.82 KMT2A (0.56) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL2351650 0.82 GABRA1 (0.60) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL830378 0.82 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL832045 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL17600644 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614229-B2 Substituted indole derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
EP-2408761-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF Schering Corporation (US) 2012-01-25 EP disclosed
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SHERING CORPORATION 2011-05-05 US disclosed
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SHERING CORPORATION 2011-05-05 US disclosed
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-05-05 US disclosed
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-05-05 US disclosed
EP-2197884-A2 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-06-23 EP disclosed
WO-2009032124-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-03-12 WO disclosed
WO-2009032123-A2 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS IDO1, IDO2, ZC3HAV1 ALDH1A1 2482/4885KDM4E 2071/4885HPGD 3175/4885
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, INMT ALDH1A1 800/4885KDM4E 1111/4885HPGD 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.